Journal of Urologic Oncology

Summarizing the Intentions and Outcomes of JUO 2023 Issue 3: Cheol Kwak; Journal of Urologic Oncology. 2023;21(3):181-182. Published online November 30, 2023; DOI: https://doi.org/10.22465/juo.23edi004; Full text PubReader ePub PDF

Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma

Influence of Body Composition on the Perioperative and Survival Outcomes of Renal Cell Carcinoma: Edouard H. Nicaise, Benjamin N. Schmeusser, Yash B. Shah, Mehmet A. Bilen, Kenneth Ogan, Viraj A. Master; Journal of Urologic Oncology. 2023;21(3):183-199. Published online November 30, 2023; DOI: https://doi.org/10.22465/juo.234600500025
Cited By 2; Full text PubReader ePub PDF

Preoperative Renal Artery Embolization Before Radical Nephrectomy for Nonmetastatic Renal Cell Carcinoma: A Propensity Score Matched Analysis: Jin Noh, Sang Hun Song, Gyoohwan Jung, Sangchul Lee, Sung Kyu Hong, Seok Soo Byun, Jung Kwon Kim; Journal of Urologic Oncology. 2023;21(3):200-207. Published online November 30, 2023; DOI: https://doi.org/10.22465/juo.234600480024
Cited By 1; Full text PubReader ePub PDF

The Future of Adjuvant Therapy in Renal Cell Carcinoma: Recent Insights and Prospects: Hyerim Ha, Joo Han Lim; Journal of Urologic Oncology. 2023;21(3):208-216. Published online November 30, 2023; DOI: https://doi.org/10.22465/juo.234600540027
Cited By 1; Full text PubReader ePub PDF

Role of Radiotherapy in Metastatic Renal Cell Carcinomas: An Evolutionary Journey in a Misunderstood Histological Type: Chan Woo Wee, Jaeho Cho; Journal of Urologic Oncology. 2023;21(3):217-227. Published online November 30, 2023; DOI: https://doi.org/10.22465/juo.234600560028
Cited By 1; Full text PubReader ePub PDF

Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer

Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023: Jiwoong Yu, Hyun Hwan Sung; Journal of Urologic Oncology. 2023;21(3):228-240. Published online November 30, 2023; DOI: https://doi.org/10.22465/juo.234600420021
Cited By 2; Full text PubReader ePub PDF

Early Experience With Pembrolizumab in Bacillus Calmette-Guérin Unresponsive Non–Muscle-Invasive Bladder Cancer: Chung Un Lee, Wan Song, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Seong Il Seo, Seong Soo Jeon, Se Hoon Park, Byong Chang Jeong; Journal of Urologic Oncology. 2023;21(3):241-248. Published online November 30, 2023; DOI: https://doi.org/10.22465/juo.234600620031
Cited By 1; Full text PubReader ePub PDF

Clinical Outcomes of Patients With Variant Histology of Urothelial Carcinoma After Radical Cystectomy: Dan Bee Lee, Jae Yeon Kim, Yun Ha Lee, Won Hoon Song, Seung Soo Lee, Sung Woo Park, Jong Kil Nam; Journal of Urologic Oncology. 2023;21(3):249-256. Published online November 30, 2023; DOI: https://doi.org/10.22465/juo.234600400020
Correction in: J Urol Oncol 2024;22(2):183
Cited By 1; Full text PubReader ePub PDF

Clinical Predictors of ARTA Response in Metastatic Prostate Cancer

Predictive Factors of Abiraterone Response in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer: Jaeyoung Cho, Jungyo Suh, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Bumjin Lim; Journal of Urologic Oncology. 2023;21(3):257-263. Published online November 30, 2023; DOI: https://doi.org/10.22465/juo.234604600023
Cited By 1; Full text PubReader ePub PDF

Nonregional Lymph Node Metastasis as a Predictor of Early Progression When Using Androgen Receptor Targeting Agents in Patients With Metastatic Castration-Resistant Prostate Cancer Without Previous Chemotherapy: Sihyeon Kim, Beom Yong Rho, Dong Hyuk Kang, Doo Yong Chung; Journal of Urologic Oncology. 2023;21(3):264-270. Published online November 30, 2023; DOI: https://doi.org/10.22465/juo.234600520026
Cited By 1; Full text PubReader ePub PDF

Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel: Tae Hwan Kim, Seol Ho Choo, Kang Hee Shim, Sun Il Kim; Journal of Urologic Oncology. 2023;21(3):271-276. Published online November 30, 2023; DOI: https://doi.org/10.22465/juo.234600440022
Cited By 1; Full text PubReader ePub PDF

Clinical Significance of Rab27a as a Urinary Biomarker in Patients With Bladder Cancer: Ja Yoon Ku, Md Nazmul Huda, Eu Chang Hwang, Chan Ho Lee, Kyung Hwan Kim, Dong Deuk Kwon, Hong Koo Ha; Journal of Urologic Oncology. 2023;21(3):277-277. Published online November 30, 2023; DOI: https://doi.org/10.22465/juo.err.kjuo.2022.20.1.52
Corrects: J Urol Oncol 2022;20(1):52; Full text PubReader ePub PDF

5,615	New Drugs for Bacillus Calmette Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer
5,064	The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer
4,410	The Present and Future of Intravesical Therapy in Bladder Cancer
4,361	An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
4,355	Complex Epidemiology of Prostate Cancer in Asian Countries

Cited By 7	Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades
Cited By 4	An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
Cited By 4	Complex Epidemiology of Prostate Cancer in Asian Countries
Cited By 3	The Evolving Role of Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma: A Literature Review of Practice-Changing Trials
Cited By 2	Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use

Previous issues